Speaker
Description
GOLDEN JUBILEE CELEBRATION 2022
POSTER COMPETITION
BIT MESRA
NOVEL BIOTHERAPEUTIC APPROACH IN COMBATING RESURRECTION OF COVID-19 Purnima Mahto, Deepika Kumari, Monika Dwivedi (Corresponding Author)
In the last two decades, many viruses have caused disease outbreaks in various parts of the world. That also includes SARS coronavirus (SARS-CoV) which was reported epidemic in 2002–2003. Influenza A, the Middle East respiratory syndrome (MERS) and the current SARS-CoV-2 are outbreaks in past two decades. However, the global spread of the novel coronavirus pandemic need of rapid treatment and accelerate the rapid development of therapeutics. To create potent medications, various studies have so far looked into and identified the underlying epidemiological and clinical traits of COVID-19 infections. Biotherapeutics can be quickly developed for COVID-19 treatments because they have unique advantages over antiviral small-molecule inhibitors, such as fewer side effects due to their high specificity. Here, we list potential biotherapeutics and explain how they work which include therapeutic antibodies, peptides, modified ACE2, probiotics, convalescent plasma, therapeutic antibodies, cytokine inhibitors, nucleic acid-based therapy, and interferon. Biotherapeutics are future interventions for relapsing Covid 19.
Keywords: COVID-19, SARS-CoV-2, therapeutic antibodies, peptides, modified ACE2, probiotics, convalescent plasma, therapeutic antibodies, cytokine inhibitors, nucleic acid-based therapy, interferon.
GRAPHICAL ABSTRACT:-